Predicting metabolic dysfunction associated steatotic liver disease using explainable machine learning methods DOI Creative Commons
Yi‐Hao Yu, Yuqi Yang, Qian Li

и другие.

Scientific Reports, Год журнала: 2025, Номер 15(1)

Опубликована: Апрель 11, 2025

Early and accurate identification of patients at high risk metabolic dysfunction-associated steatotic liver disease (MASLD) is critical to prevent improve prognosis potentially. We aimed develop validate an explainable prediction model based on machine learning (ML) approaches for MASLD among the adult population. The national cross-sectional study collected data from National Health Nutrition Examination Survey 2017 2020, consisting 13,436 participants, who were randomly split into 70% training, 20% internal validation, 10% external validation cohorts. was defined transient elastography cardiometabolic factors. With 50 medical characteristics easily obtained, six ML algorithms used models. Several evaluation parameters compare predictive performance, including area under receiver-operating-characteristic curve (AUC) precision-recall (P-R) curve. recursive feature elimination method applied select optimal subset. Shapley Additive exPlanations offered global local explanations model. random forest (RF) performed best in discriminative ability 6 models, 10-feature RF finally chosen. final could accurately predict cohorts (AUC: 0.928, 0.918; P-R curve: 0.876, 0.863, respectively). better than each traditional indicators MASLD. An with excellent discrimination calibration performance successfully developed validated clinical extracted using algorithm.

Язык: Английский

Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges DOI Open Access
Michail Kokkorakis, Chrysoula Boutari, Michael A. Hill

и другие.

Metabolism, Год журнала: 2024, Номер 154, С. 155835 - 155835

Опубликована: Март 19, 2024

Язык: Английский

Процитировано

82
Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD DOI Creative Commons
Farah Abdelhameed, Chris Kite, Lukasz Lagojda

и другие.

Current Obesity Reports, Год журнала: 2024, Номер 13(3), С. 510 - 531

Опубликована: Май 29, 2024

The prevalence of non-alcoholic fatty liver disease (NAFLD) is rapidly increasing worldwide, making it the leading cause related morbidity and mortality. Currently, biopsy gold standard for assessing individuals with steatohepatitis fibrosis. However, its invasiveness, sampling variability, impracticality large-scale screening has driven search non-invasive methods early diagnosis staging. In this review, we comprehensively summarise evidence on diagnostic performance limitations existing serum biomarkers scores in evaluation steatosis, steatohepatitis,

Язык: Английский

Процитировано

45
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies DOI Open Access
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek

и другие.

Pharmacological Reviews, Год журнала: 2024, Номер 76(3), С. 454 - 499

Опубликована: Янв. 30, 2024

Steatotic liver disease (SLD) displays a dynamic and complex phenotype. Consequently, the metabolic dysfunction-associated steatotic (MASLD)/metabolic steatohepatitis (MASH) therapeutic pipeline is expanding rapidly in multiple directions. In parallel, non-invasive tools for diagnosing monitoring responses to interventions are being studied, clinically feasible findings explored as primary outcomes interventional trials. The realization that distinct subgroups exist under umbrella of SLD should guide more precise personalized treatment recommendations facilitate advancements pharmacotherapeutics. This review summarizes recent updates pathophysiology-based nomenclature outlines both effective pharmacotherapeutics those MASLD/MASH, detailing their mode action current status phase 2 3 clinical Of extensive arsenal MASLD/MASH pipeline, several have been rejected, whereas other, mainly monotherapy options, shown only marginal benefits now tested part combination therapies, yet others still development monotherapies. Although successful drug candidate (or combinations) remains elusive, such approaches will ideally target MASH fibrosis while improving cardiometabolic risk factors. Due urgent need novel strategies potential availability safety tolerability data, repurposing existing approved drugs an appealing option. Finally, it essential highlight and, by extension, MASLD be recognized approached systemic affecting organs, with vigorous implementation interdisciplinary coordinated plans. Significance Statement SLD, including, among others, MASH, considered most prevalent chronic condition than one-fourth global population. aims provide information regarding pathophysiology, diagnosis, management line guidelines Collectively, hoped provided furthers understanding state direct implications stimulates additional research initiatives.

Язык: Английский

Процитировано

36
DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases DOI Creative Commons
Yehuda Handelsman,

John E. Anderson,

George L. Bakris

и другие.

Metabolism, Год журнала: 2024, Номер 159, С. 155931 - 155931

Опубликована: Июнь 7, 2024

Язык: Английский

Процитировано

24
Metabolic dysfunction-associated steatotic liver disease: Recent turning points for its diagnosis and management DOI
Stergios A. Pοlyzos, Christos S. Mantzoros

Metabolism, Год журнала: 2024, Номер 157, С. 155936 - 155936

Опубликована: Май 17, 2024

Язык: Английский

Процитировано

11
A European Survey to Identify Challenges in the Management of Metabolic Dysfunction‐Associated Steatotic Liver Disease DOI Creative Commons
Laurent Castéra, William Alazawi, Elisabetta Bugianesi

и другие.

Liver International, Год журнала: 2025, Номер 45(2)

Опубликована: Янв. 3, 2025

ABSTRACT Background and Aims Metabolic dysfunction‐associated steatotic liver disease (MASLD) its more severe subtype, metabolic steatohepatitis (MASH), are highly prevalent strongly associated with obesity type 2 diabetes (T2D). This study sought to identify challenges the diagnosis, treatment management of people living MASLD MASH understand key barriers adopting relevant clinical guidelines. Methods A real‐world, cross‐sectional (BARRIERS‐MASLD) consisting a quantitative survey qualitative interviews physicians in France, Germany, Italy, Spain United Kingdom was conducted from March September 2023. Descriptive statistics were used for data analysis. Results total 626 completed survey; n = 10 each country participated interviews. Physicians considered presence be impactful on how they treated (66%) T2D (69%). Over one‐third (35%) respondents could not any MASH‐specific guidelines issued by medical societies or associations top‐of‐mind, but overall awareness rose when prompted about country‐specific said would need evidence success (48%) that address common comorbidities (38%) increase their adoption. Conclusions found lack around clearly established care pathways, particularly addressing comorbidities, factor preventing optimising Europe. research highlights opportunities improve education training coordination.

Язык: Английский

Процитировано

1
Milestones in the journey towards addressing obesity; Past trials and triumphs, recent breakthroughs, and an exciting future in the era of emerging effective medical therapies and integration of effective medical therapies with metabolic surgery DOI Open Access
Michail Kokkorakis, Angeliki Katsarou, Niki Katsiki

и другие.

Metabolism, Год журнала: 2023, Номер 148, С. 155689 - 155689

Опубликована: Сен. 7, 2023

Язык: Английский

Процитировано

22
Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study DOI
Laura Valenzuela‐Vallejo, Pavlina Chrysafi, Matina Kouvari

и другие.

Metabolism, Год журнала: 2023, Номер 148, С. 155694 - 155694

Опубликована: Сен. 25, 2023

Язык: Английский

Процитировано

20
Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease DOI Open Access
Laura Valenzuela‐Vallejo, Despina Sanoudou, Christos S. Mantzoros

и другие.

Journal of Personalized Medicine, Год журнала: 2023, Номер 13(5), С. 830 - 830

Опубликована: Май 14, 2023

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic disease, and related to fatal non-fatal liver, metabolic, cardiovascular complications. Its non-invasive diagnosis effective treatment remain an unmet clinical need. NAFLD a heterogeneous that commonly present in context of metabolic syndrome obesity, but not uncommonly, may also be without abnormalities subjects with normal body mass index. Therefore, more specific pathophysiology-based subcategorization (FLD) needed better understand, diagnose, treat patients FLD. A precision medicine approach for FLD expected improve patient care, decrease long-term outcomes, develop better-targeted, treatments. We herein based on our recently proposed subcategorization, which includes metabolic-associated (MAFLD) (i.e., obesity-associated (OAFLD), sarcopenia-associated (SAFLD, lipodystrophy-associated (LAFLD)), genetics-associated (GAFLD), multiple/unknown causes (XAFLD), combined (CAFLD) as well advanced stage fibrotic (FAFLD) end-stage (ESFLD) subcategories. These other advances, whole, are enable only improved quality life, considerable reduction healthcare system costs associated FLD, along options treatments near future.

Язык: Английский

Процитировано

18
Thyroid function, adipokines and mitokines in metabolic dysfunction‐associated steatohepatitis: A multi‐centre biopsy‐based observational study DOI Creative Commons
Matina Kouvari, Laura Valenzuela‐Vallejo,

Evangelos Axarloglou

и другие.

Liver International, Год журнала: 2024, Номер 44(3), С. 848 - 864

Опубликована: Янв. 23, 2024

Abstract Background and Aims Thyroid axis is currently under investigation as a therapeutic target in metabolic dysfunction‐associated steatotic liver disease (MASLD). function was examined herein the full spectrum of disease. Methods Subjects were recruited had biopsies two Gastroenterology‐Hepatology Clinics (Greece Australia) one Bariatric‐Metabolic Surgery Clinic (Italy). The main working sample n = 677 subjects with MASLD after excluding abnormal free thyroxine levels. Participants classified according to thyroid‐stimulating hormone (TSH) standard criteria: Subclinical hyperthyroidism (<0.4 uIU/mL); Euthyroidism relatively low (0.4 <2.5 euthyroidism high (2.5–4.0 subclinical hypothyroidism (>4 uIU/mL). Results TSH continuous variable positively associated significant fibrosis ( F ≥ 2), steatohepatitis (MASH) at‐risk MASH. 2 (odds ratio [OR] 3.47, 95% confident interval [CI] [1.50, 8.05], p .02), MASH (OR 3.44, CI [1.48, 7.98] .001) 3.88, [1.76, 8.55], .001), before controlling for adiposity, central obesity, insulin resistance. When leptin, adiponectin, or growth differentiation factor‐15 moderators, significance lost. Sex‐specific analysis revealed strong association between presence among women, eliminated only when adipokines/mitokines adjusted for. Restricted cubic spline associations outcomes ‐values < .01) inflection points being 2.49, 2.67 6.96. Conclusions These observations provide support studies on administration thyroid therapeutics liver‐specific receptor agonists across continuum.

Язык: Английский

Процитировано

7